-

Twist Bioscience to Present at JSNN NanoImpacts 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022 in Greensboro, NC.

Mr. Hellmold will participate in the panel “Perspectives on SemiSynBio: Progress to Date; What’s Missing? And What’s Next?” on Thursday, October 13 at 2:10 PM ET. He will give a keynote speech on Friday, October 14 at 9:00 AM ET on progress being made towards delivering DNA data storage at scale.

The NanoImpacts 2022 Conference highlights progress being made towards achieving goals laid out in the 2018 SemiSynBio Roadmap (SSBR), refines the vision for future initiatives and explores potential synthetic biology and nanomaterial processes and application opportunities beyond the scope of the SSBR.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Contacts

For Twist Bioscience:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com

Industry:

Twist Bioscience Corporation

NASDAQ:TWST
Release Versions
English

Contacts

For Twist Bioscience:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com

More News From Twist Bioscience Corporation

Twist Bioscience Launches MRD Express with Rapid Turnaround Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research, biomarker discovery and assay development. Molecular residual disease (MRD) is the presence...

Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG with SPR binding characterization. Twist Express Screening Antibodies accelerate the path from sequence to purified antibody and binding characterization across br...

Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth quarter and full year ended September 30, 2026, before the opening of the market on November 12, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update...
Back to Newsroom